Triple-negative breast cancer: treatment challenges and solutionsGuy Jérusalem, Laurence Lousberg, Joëlle Collignon et al.|Breast Cancer Targets and Therapy|2016Cited by 382
Cardio-Oncology Services: rationale, organization, and implementationPatrizio Lancellotti, Riccardo Asteggiano, Alexander R. Lyon et al.|European Heart Journal|2018Cited by 303
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysisMario Giuliano, Daniele Generali, Francesco Schettini et al.|The Lancet Oncology|2019Cited by 193
Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Daniele Generali, Fabiola Giudici et al.|JNCI Journal of the National Cancer Institute|2020Cited by 102
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Tanios Bekaii‐Saab, Nobumasa Mizuno et al.|Journal of Clinical Oncology|2023Cited by 100